Go to the list of all blogs
Joma Foster's Avatar
published in Blogs
Apr 15, 2026
TSMC (TSM) Q1 2026 Earnings Preview: Strong AI Demand in Focus

TSMC (TSM) Q1 2026 Earnings Preview: Strong AI Demand in Focus

Key Takeaways

  • Analysts expect Q1 2026 EPS of $3.29, up 55% year-over-year from $2.12.
  • Consensus revenue forecast at $35.5 billion, aligning with TSMC's guidance of $34.6-35.8 billion and implying 39% growth.
  • March revenue surged 45% YoY to NT$415.19 billion, pushing Q1 total to NT$1,134.10 billion (~$35.7 billion), beating estimates.
  • Gross margin guidance of 63-65%, supported by higher AI chip mix (high-performance computing).
  • TSMC has beaten EPS estimates in the last four quarters, averaging ~7% surprises.
  • Full-year 2026 revenue growth outlook at ~30%, driven by AI infrastructure demand.

Why TSMC's Upcoming Earnings Matter to Investors

As the world's largest contract chipmaker, Taiwan Semiconductor Manufacturing Company (TSMC) plays a pivotal role in advanced semiconductors, crafting chips for major clients like Nvidia and Apple. With the Q1 2026 earnings report set for April 16, I'm paying close attention to how booming AI demand continues to offset seasonal weakness in smartphones. TSMC's revenue has accelerated sharply, as seen in Q4 2025's $33.73 billion (up 25.5% YoY), driven by high-performance computing (HPC) now accounting for over 50% of wafer revenue. Investors like us are looking for reassurance on sustained AI momentum, margin improvements, and capital expenditure plans of $52-56 billion for 2026. These results often set the tone for the entire semiconductor sector and its supply chain.

What to Expect from Q1 Results

Wall Street is forecasting solid performance for TSMC's Q1 2026 (January-March). Consensus EPS stands at $3.29 per ADR, marking a 55% increase from $2.12 in Q1 2025, according to Zacks data. Revenue expectations are $35.5 billion, fitting neatly within TSMC's guidance of $34.6-35.8 billion (based on USD/NTD at 31.6), which points to 39% YoY growth from ~$25.5 billion. The preliminary monthly figures back this up: Q1 revenue reached NT$1,134.10 billion (~$35.7 billion), a 35% YoY rise that exceeded LSEG estimates of NT$1,125 billion, with March alone hitting NT$415.19 billion (+45% YoY).

From what I see, key metrics like gross margins of 63-65% (improved from Q4's 62.3%) and operating margins of 54-56% should benefit from a greater AI/HPC mix. TSMC has a strong track record of beating expectations: Q4 2025 EPS came in at $3.14 versus $2.98 (+5.5%), Q3 at $2.92 versus $2.63 (+11%), and similar outperformance in prior quarters. One thing that stands out is the focus on Q2 guidance, progress on 2nm process yields, and any fresh signals on AI demand from key customers.

Market Sentiment and Potential Reactions

Heading into earnings, sentiment around TSM remains positive, with shares up ~29% YTD on AI enthusiasm. The March revenue beat drove a 2.3% gain in Taipei trading. Historically, TSM has climbed post-earnings in 9 of the last 12 instances (average +2.2% on day 1), though it has averaged -1.9% when missing. Risks worth noting include geopolitical tensions in the Taiwan Strait and Middle East supply chains, softness in smartphones and PCs, and lofty expectations—Zacks Earnings ESP of +2.77% suggests a potential beat. Options pricing points to a ~6-7% move after the report.

Using Tickeron's AI Screener in My Analysis

In reviewing TSM's positioning, I turned to Tickeron’s AI Screener, an AI-powered tool for discovering stocks and ETFs. It lets me filter thousands of assets using customizable criteria like technical patterns, fundamentals, trends, volatility, and AI signals—such as industry peers, market cap, indicators, price patterns, and performance metrics. This helps pinpoint trade ideas, trending names, breakouts, and opportunities far more efficiently than manual scans. I find it particularly useful for contextualizing TSM against the semiconductor space; if you're screening for AI-related plays, it's worth exploring to streamline your research.

Looking Ahead: Growth Drivers and What I'm Watching

TSMC has guided for ~30% full-year 2026 revenue growth in USD terms, which analysts view as conservative given AI tailwinds. Q1's record revenue underscores HPC/AI as the primary growth driver, with advanced nodes (3nm/5nm/7nm) comprising ~77% of wafer revenue in Q4.

I'm watching Q2 guidance closely, where analysts anticipate high-single-digit quarter-over-quarter growth. Margins could face headwinds from overseas fabs like the US/Arizona expansions, but pricing power on advanced nodes and high utilization rates provide support. The $52-56 billion capex plan emphasizes 2nm (risk production in 2026) and A16 technology tailored for AI.

Demand updates from Nvidia and Apple, the ramp in AI inference, and any recovery in PCs/smartphones will be telling. Geopolitical factors like US-China tensions and Middle East supply issues introduce volatility. Keep an eye on 2nm yields and customer "strong signals" for longer-term visibility—in my view, this balanced exposure to AI remains a key focal point.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations

Related Ticker: TSM

TSM in upward trend: 10-day moving average moved above 50-day moving average on September 08, 2026

The 10-day moving average for TSM crossed bullishly above the 50-day moving average on September 08, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 16, 2026. You may want to consider a long position or call options on TSM as a result. In 59 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.

The Moving Average Convergence Divergence (MACD) for TSM just turned positive on September 18, 2026. Looking at past instances where TSM's MACD turned positive, the stock continued to rise in 35 of 45 cases over the following month. The odds of a continued upward trend are 78%.

TSM moved above its 50-day moving average on September 16, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +5.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where TSM advanced for three days, in 234 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.

The Aroon Indicator entered an Uptrend today. In 219 of 282 cases where TSM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TSM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.

TSM broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 5 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 71, placing this stock better than average.

The Tickeron SMR rating for this company is 26 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. TSM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (11.614) is normal, around the industry mean (7.902). P/E Ratio (33.701) is within average values for comparable stocks, (163.223). Projected Growth (PEG Ratio) (0.859) is also within normal values, averaging (3.705). Dividend Yield (0.008) settles around the average of (0.007) among similar stocks. P/S Ratio (15.480) is also within normal values, averaging (45.163).

Notable companies

The most notable companies in this group are NVIDIA Corp (NASDAQ:NVDA), Taiwan Semiconductor Manufacturing Company Ltd (NYSE:TSM), Broadcom Inc. (NASDAQ:AVGO), Micron Technology (NASDAQ:MU), Advanced Micro Devices (NASDAQ:AMD), Intel Corp (NASDAQ:INTC), Texas Instruments (NASDAQ:TXN), Marvell Technology (NASDAQ:MRVL), QUALCOMM (NASDAQ:QCOM), Analog Devices (NASDAQ:ADI).

Industry description

The semiconductor industry manufacturers all chip-related products, including research and development. These chips are used in innumerable electronic devices, including computers, cell phones, smartphones, and GPSs. Intel Corporation, NVIDIA Corp., and Broadcomm are some of the prominent players in this industry. Semiconductor companies usually tend to do well during periods of healthy economic growth, thereby inducing further research and development in the industry – which in turn augurs well for productivity and growth in the economy. In the near future, demand for semiconductor products (and possibly innovation within the segment) should only expand further, with the proliferation of 5G, autonomous vehicles, IoT, and various AI-driven electronics set to herald a new, advanced chapter in the technology-driven world as we know it. With burgeoning prospects comes great competition. In 2015, SIA estimated that U.S. semiconductor industry ranks as the second most competitive U.S. industry out of 2882 U.S. industries designated manufacturers by the U.S. Census Bureau.

Market Cap

The average market capitalization across the Semiconductors Industry is 216.18B. The market cap for tickers in the group ranges from 86.8K to 5.53T. NVDA holds the highest valuation in this group at 5.53T. The lowest valued company is STRB at 86.8K.

High and low price notable news

The average weekly price growth across all stocks in the Semiconductors Industry was 5%. For the same Industry, the average monthly price growth was 12%, and the average quarterly price growth was 51%. WOLF experienced the highest price growth at 22%, while MOBX experienced the biggest fall at -25%.

Volume

The average weekly volume growth across all stocks in the Semiconductors Industry was 5%. For the same stocks of the Industry, the average monthly volume growth was -0% and the average quarterly volume growth was -57%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 51
Price Growth Rating: 41
SMR Rating: 72
Profit Risk Rating: 71
Seasonality Score: 20 (-100 ... +100)
View a ticker or compare two or three
TSM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of integrated circuits, silicon wafers, diodes and related semiconductor components

Industry Semiconductors

Industry
Semiconductors
Address
No. 8, Li-Hsin Road 6
Phone
+886 35636688
Employees
76907
Web
https://www.tsmc.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.